Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop

Abstract

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically associated with the t(11;14) chromosomal translocation, resulting in overexpression of cyclin D1. Although MCL is associated with clinical heterogeneity, outcomes are generally poor and no standard treatment has been established. However, the recent approval of ibrutinib provides a new therapeutic option. Moreover, recent clinical trials have provided new perspectives on the relative efficacy and safety of various approaches for both transplant-eligible and transplant-ineligible patients. Multiple novel strategies are being evaluated in the treatment of MCL, including both targeted agents and cellular immunotherapies. At the Lymphoma Research Foundation’s 12th MCL Workshop, researchers gathered to discuss research findings, clinical trial results, and future directions related to MCL, its biology, and its treatment. This manuscript, which includes a summary of each presentation, aims to review recent findings in MCL research and highlight potential areas for future study.

Keywords:

• Lymphoma and Hodgkin’s disease
• immunotherapy
• pharmacotherapeutics
• marrow and stem cell transplantation
• clinical results
• tumor microenvironment

Potential conflict of interest

All coauthors are members of the LRF MCL Consortium Executive Committee; BSK, LIG, and ES are also members of the Foundation’s Scientific Advisory Board. These proceedings were drafted with assistance from freelance writer Melinda B. Tanzola, PhD and LRF Staff Member Whitney Steen. Disclosure forms provided by the authors are available with the full text of this article online at http://dx.doi.org/10.1080/10428194.2017.1283036